Congratulation for all those bought yesterday and today morning. As forecasted it closed at 0.70 Our next strategy is to close above 0.735 Solution will be the darling stock over the next few months. Prepare to hold for exceptional profit.
Cansino is in phase 3, so far the closest to the final stage i think. The most important is Cansino is co-operate with the ChenWei who was commanded to settle the "issue"of the WuHan Lab.
“It is important that we want to be at the front end of the queue for vaccination, but it has to be safe and effective. We must look at the data first, which is expected to come out next month or in December,” Khairy said.
"CanSino Biologics, Johnson & Johnson, and the University of Oxford are all using genetically engineered common cold viruses to make COVID-19 vaccines."
I am not putting these GENETICALLY ENGINEERED vaccines into my body
"CanSino Biologics, Johnson & Johnson, and the University of Oxford are all using genetically engineered common cold viruses to make COVID-19 vaccines."
I am not putting these GENETICALLY ENGINEERED vaccines into my body
CanSino Biologics/Beijing Institute of Biotechnology CanSino Biologics, in collaboration with the Beijing Institute of Biotechnology, developed a candidate vaccine using a weakened adenovirus. Unlike the Oxford vaccine, which relies on an adenovirus that infects chimpanzees, CanSino Biologics is using an adenovirus that infects humans.
Along with Moderna, this group also published results from their phase 2 trial on July 20 in the journal The Lancet. The trial, which was conducted in Wuhan (where the first coronavirus cases emerged), involved 508 participants who were randomly assigned to receive either one of two different doses of the vaccine or a placebo.
This study also didn't find serious adverse events, though some reported mild or moderate reactions including fever, fatigue and injection site pain. Around 90% of the participants developed T-cell responses and about 85% developed neutralizing antibodies, according to the study.
NEW YORK: A division of Chinese state-run Sinopharm Group that is developing two COVID-19 vaccines is offering them for free to Chinese students going abroad for higher studies, the Wall Street Journal reported on Wednesday (Oct 14).
The move by China National Biotec Group (CNBG) is aimed at boosting public confidence in homegrown inoculations, the Journal reported, citing a company website and some students who applied for it.
The announcement of the company distributing vaccines to students appeared on a website where people could sign up to receive it, the newspaper reported.
READ: China to purchase COVAX vaccines for 1% of population, says foreign ministry The website said on Monday that 481,613 people had taken the vaccine while an additional 93,653 had applied to be inoculated, according to the report.
A fourth vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June.
On the other hand, an Abu Dhabi-based artificial intelligence and cloud computing company called Group 42 is nearing the end of Phase III clinical trials of a vaccine in partnership with CNBG.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Leo8909
67 posts
Posted by Leo8909 > 2020-10-16 16:54 | Report Abuse
GOOD NEWS!